Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine
Abstract
Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over‐expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti‐EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico‐chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti‐EGFR (BSA‐Gem‐EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA‐Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface. Copyright © 2012 John Wiley & Sons, Ltd.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
More studies have proven that the CTX-modified nano-drug carrier system has better targeting and exerts a stronger tumor suppressor effect.
“More studies have also proven that the CTX-modified nano-drug carrier system has better targeting and exerts a stronger tumor suppressor effect.196–198”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [198]
Cites
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029 · see citing works
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,112 · see citing works
Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Buchier, M., & Beger, H. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116001 · Cited by 492 · see citing works
Basu, S., Nagy, J. A., Pal, S., Vasile, E., Eckelhoefer, I. A., Bliss, V. S., Manseau, E. J., Dasgupta, P., Dvorak, H. F., & Mukhopadhyay, D. (2001) · Nature Medicine · doi:10.1038/87895 · Cited by 396 · see citing works
Self-citationTargeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
Patra, C. R., Bhattacharya, R., Wang, E., Katarya, A., Lau, J. S., Dutta, S. K., Muders, M. H., Wang, S., Buhrow, S. A., Safgren, S. L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6102 · Cited by 372 · see citing works
Self-citationDiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K. M., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2003) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361 · see citing works
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Mendelsohn, J. M. (1997) · PubMed · Cited by 311 · see citing works
Protein microencapsulation of nonaqueous liquids
Suslick, K. S., & Grinstaff, M. W. (1990) · Journal of the American Chemical Society · doi:10.1021/ja00177a058 · Cited by 272 · see citing works
Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting
Tseng, C.-L., Wang, T.-W., Dong, G., Wu, S. Y.-H., Young, T., Shieh, M., Lou, P., & Lin, F. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.006 · Cited by 160 · see citing works
Characterization of sonochemically prepared proteinaceous microspheres
Suslick, K. S., Grinstaff, M. W., Kolbeck, K. J., et al. (1994) · Ultrasonics Sonochemistry · doi:10.1016/1350-4177(94)90030-2 · Cited by 123 · see citing works
Buchsbaum, D. J., Bonner, J. A., Grizzle, W. E., et al. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03788-4 · Cited by 111 · see citing works
Hanes, J. S., Sills, A. K., Zhao, Z., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1010963307097 · Cited by 95 · see citing works
A novel method for the preparation of biodegradable microspheres for protein drug delivery
Pareta, R. A., & Edirisinghe, M. J. (2006) · Journal of The Royal Society Interface · doi:10.1098/rsif.2006.0120 · Cited by 90 · see citing works
Growth Factor Receptors Are Differentially Expressed in Cancers of the Papilla of Vater and Pancreas
Frieß, H., Wang, L., Zhu, Z., Gerber, R., Schröder, M., Fukuda, A., Zimmermann, A., Korc, M., & Büchler, M. W. (1999) · Annals of Surgery · doi:10.1097/00000658-199912000-00005 · Cited by 79 · see citing works
Lev, S. A., Nitzan, Y., Dror, R., et al. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036834+ · Cited by 61 · see citing works
Human monoclonal antibodies directed against melanoma tumor-associated antigens.
Kan‐Mitchell, J., Imam, A., Kempf, R. A., et al. (1986) · PubMed · Cited by 58 · see citing works
Grinberg, O., Hayun, M., Sredni, B., & Gedanken, A. (2007) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2006.11.004 · Cited by 56 · see citing works
Self-citationDevelopment of protein delivery microsphere system by a novel S/O/O/W multi-emulsion
Yuan, W., Wu, F., Guo, M., & Jin, T. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.08.009 · Cited by 52 · see citing works
Grinberg, O., Gedanken, A., Patra, C. R., et al. (2009) · Acta Biomaterialia · doi:10.1016/j.actbio.2009.05.003 · Cited by 45 · see citing works
Self-citationScott, C. J., Marouf, W. M., Quinn, D. J., Buick, R. J., Orr, S. J., Donnelly, R. F., & McCarron, P. A. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9400-7 · Cited by 43 · see citing works
Targeting of Human Squamous Carcinomas by SPA470-doxorubicin Immunoconjugates
Hebert, C. G., Norris, K., & Sauk, J. J. (2003) · Journal of drug targeting · doi:10.1080/1061186031000121478 · Cited by 19 · see citing works
LINING UP TO MAKE A CANCER DRUG
McCoy, M. (2004) · Chemical & Engineering News · doi:10.1021/cen-v082n035.p012 · Cited by 15 · see citing works
Controlled release from glutaraldehyde crosslinked gelatin microspheres
Muvaffak, A., & Hasırcı, N. (2002) · Technology and Health Care · Cited by 12 · see citing works
Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF
Paridaens, R., Lyman, G. H., Leonard, R. C., et al. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)00082-x · Cited by 5 · see citing works
The Use of Antibodies in Diagnosis and Therapy of Cancer
Muvaffak, A., & Hasırcı, N. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0063-6_23 · Cited by 4 · see citing works
The EGF receptor system as a target for therapy
Normanno, N. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)71178-9 · Cited by 2 · see citing works
Dubreuil, R. R., Souik, P., Haines, G. K., et al. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570720 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works
- Authors
- Grinberg, O., Gedanken, A., Mukhopadhyay, D., & Patra, C. R.
- Affiliations
- Bar-Ilan University (IL)
- Mayo Clinic (US)
- Indian Institute of Chemical Technology (IN)
- Corresponding author
- Gedanken, Aharon
- Venue
- Polymers for Advanced Technologies
- Publisher
- Wiley
- Published
- 2012-10-23
- Volume
- 24
- Issue
- 3
- Pages
- 294-299
- ISSN
- 1042-7147 (ISSN-L)
- 1099-1581
- OpenAlex
- W2161968729
- Cited by
- 16
- References
- 27
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 2
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Polymers for Advanced Technologies (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- gemcitabine, targeted drug delivery, anti-EGFR monoclonal antibody, EGFR overexpression, pancreatic cancer, AsPC-1 cells, EGFR signaling inhibition, anticancer drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
